Prognostic significance of connective tissue growth factor expression in stromal cells in patients with diffuse‑type gastric cancer
View abstract on PubMed
Summary
This summary is machine-generated.Low connective tissue growth factor (CTGF) expression in gastric cancer (GC) stromal cells is linked to worse survival, particularly in diffuse-type GC. CTGF may be a therapeutic target for this subtype.
Area Of Science
- Oncology
- Molecular Biology
- Signaling Pathways
Background
- Connective tissue growth factor (CTGF) is a downstream target of the Hippo signaling pathway.
- The specific role of CTGF in different histological types of gastric cancer (GC) is not well understood.
Purpose Of The Study
- To investigate the clinical significance of CTGF expression in both cancer and stromal cells within various histological types of GC.
- To explore the association between CTGF expression and clinicopathological factors in GC patients.
Main Methods
- Analysis of CTGF expression using immunohistochemistry in 589 GC patients.
- Utilized The Cancer Genome Atlas (TCGA) database for CTGF mRNA expression and clinical data.
- Correlated CTGF expression with clinicopathological features and overall survival (OS).
Main Results
- CTGF expression was detected in the cytoplasm of GC cancer and stromal cells.
- Stromal CTGF expression correlated significantly with cancer cell CTGF expression.
- Low stromal CTGF expression was an independent predictor of worse OS, especially in diffuse-type GC.
Conclusions
- Reduced CTGF expression in stromal cells is associated with poorer prognosis in diffuse-type GC patients.
- CTGF and its regulation by the Hippo pathway represent potential therapeutic targets for diffuse-type GC.

